Cargando…

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms

The tumour suppressor BRCA1-associated protein 1 (BAP1) is the most frequently mutated cancer gene in mesothelioma. Here we report novel functions for BAP1 in mitotic progression highlighting the relationship between BAP1 and control of genome stability in mesothelioma cells with therapeutic implica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Anita, Busacca, Sara, Gaba, Aarti, Sheaff, Michael, Poile, Charlotte, Nakas, Apostolos, Dzialo, Joanna, Bzura, Aleksandra, Dawson, Alan G., Fennell, Dean A., Fry, Andrew M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937923/ https://www.ncbi.nlm.nih.gov/pubmed/36550359 http://dx.doi.org/10.1038/s41388-022-02577-3

Ejemplares similares

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
por: Zhang, Min, et al.
Publicado: (2021)

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
por: Zhang, Min, et al.
Publicado: (2021)

Precision Therapy for Mesothelioma: Feasibility and New Opportunities
por: Dulloo, Sean, et al.
Publicado: (2021)

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial
por: Fennell, Dean A., et al.
Publicado: (2022)

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells
por: Kolluri, Krishna Kalyan, et al.
Publicado: (2018)

Germline BAP1 mutations predispose to malignant mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2011)

BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma
por: Murrone, Albero, et al.
Publicado: (2021)

Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
por: Pulford, Emily, et al.
Publicado: (2017)

BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma
por: Busacca, Sara, et al.
Publicado: (2013)

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
por: Ladanyi, Marc, et al.
Publicado: (2019)

Correction: BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma
por: Busacca, Sara, et al.
Publicado: (2013)

BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
por: Ishii, Yuki, et al.
Publicado: (2021)

BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
por: Carbone, Michele, et al.
Publicado: (2012)

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma
por: Alakus, Hakan, et al.
Publicado: (2015)

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
por: Guazzelli, Alice, et al.
Publicado: (2019)

The Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma
por: Gupta, Aanchal, et al.
Publicado: (2021)

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma
por: Carbone, Michele, et al.
Publicado: (2023)

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma
por: Kalra, Neetu, et al.
Publicado: (2015)

Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report
por: MacLean, Alyssa, et al.
Publicado: (2022)

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
por: Shrestha, Raunak, et al.
Publicado: (2019)

Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health
por: Vimercati, Luigi, et al.
Publicado: (2022)

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres
por: Fennell, Dean, et al.
Publicado: (2023)

BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
por: Barnett, Sarah E., et al.
Publicado: (2023)

Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members
por: Kittaneh, Muaiad, et al.
Publicado: (2018)

Genes versus Environment: cytoplasmic BAP1 determines the toxic response to environmental stressors in mesothelioma
por: Amelio, Ivano
Publicado: (2017)

A case of slowly progressive malignant pericardial mesothelioma suggesting the involvement of BAP1 loss
por: Fukasawa, Naoto, et al.
Publicado: (2022)

Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
por: Zuccatosta, Lina, et al.
Publicado: (2023)

Commentary: Case report: Mesothelioma and BAP1 tumor predisposition syndrome: implications for public health
por: Sassorossi, Carolina, et al.
Publicado: (2023)

CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma
por: Karnan, Sivasundaram, et al.
Publicado: (2023)

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
por: Fennell, Dean A, et al.
Publicado: (2021)

BAP1 Malignant Pleural Mesothelioma Mutations in Caenorhabditis elegans Reveal Synthetic Lethality between ubh-4/BAP1 and the Proteasome Subunit rpn-9/PSMD13
por: Martínez-Fernández, Carmen, et al.
Publicado: (2023)

Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome
por: Lalloo, Fiona, et al.
Publicado: (2023)

Clinical and Molecular Validation of BAP1, MTAP, P53, and Merlin Immunohistochemistry in Diagnosis of Pleural Mesothelioma
por: Chapel, David B., et al.
Publicado: (2022)

Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
por: Andrici, Juliana, et al.
Publicado: (2015)

Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
por: Kushitani, Kei, et al.
Publicado: (2018)

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
por: Ghafoor, Azam, et al.
Publicado: (2021)

Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response
por: Osmanbeyoglu, Hatice Ulku, et al.
Publicado: (2022)

BAP1 Tumour Predisposition Syndrome Due to Whole BAP1 Gene Deletion
por: Pandithan, Dinusha, et al.
Publicado: (2022)

BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome
por: Blatnik, Ana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_du9salgvdup3mljgc6ca8rh73m